The SIMM study: Survey of integrative medicine in myeloproliferative neoplasms.

Diet and Risk of Myeloproliferative Neoplasms in Older Individuals from the NIH-AARP Cohort.

Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase.

Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study.

How and When to Manage Ruxolitinib Failure in Myelofibrosis.

Management of challenging myelofibrosis after JAK inhibitor failure and/or progression.

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

Management of myelofibrosis after ruxolitinib failure.

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.

Carotenoid Intake and Circulating Carotenoids Are Inversely Associated with the Risk of Bladder Cancer: A Dose-Response Meta-analysis.